Effekten av COVID-19 på behandlingen av neovaskulär AMD i Sverige – Data från Svenska Makularegistret

Isac Wickman, Monica Lövestam-Adrian, Elisabet Granstam, Ulrika Kjellström, Marion Schroeder

SVENSKA MAKULA REGISTRET

Bakgrund

Graefe's Archive for Clinical and Experimental Ophthalmology (2020) 258:1149–1156
https://doi.org/10.1007/s00417-020-04703-x

REVIEW ARTICLE

Guidance for anti-VEGI during the COVID-19 p

Jean-François Korobelnik[1,2] · Ana
George N. Lambrou[7] · Paolo Lanz
Annabelle A. Okada[14] · Ian Pearce

Received: 7 April 2020 / Revised: 10 April 202

Abstract
Purpose There is an urgent need to ad
injections with anti-vascular endotheli
guidance for ophthalmologists on how
Methods The Vision Academy's Ste
ations for managing patients with ret
issue, members put forward recomm
Results The considerations focus on
COVID-19. These include the use of
pre-screening to identify symptomati
include triaging of patients to identify
monitoring visits where possible. I
regimens that require frequent monit
Conclusion Management of patients v
adjustment to regular clinical practice
greatest medical need. The safety of p

Nationellt programområde NPO Ögonsjukdomar. NAG Medicinsk retina

Handläggning av medicinska retinapatienter under Covid-19.

Utarbetat av NAG Medicinsk retina. Godkänt av NPO Ögonsjukdomar 200416

Figur 4. Covid-19. Antal registrerade besök och antal registrerade behandlingar per månad under 2019-2021.



Frågeställning

1-årsuppföljning

Att jämföra behandlingen och visusutfall hos två grupper av patienter med neovaskulär åldersrelaterad makuladegeneration (nAMD) före och under det första året av COVID-19-pandemin i Sverige.

Tidslinje

Före Covid-19 pandemin
Inklusionsperiod:
Juli 2018 - Jan 2019

I början av Covid-19 pandemin
Inklusionsperiod:
Feb 2020 - Aug 2020

Ursprungligen 2974 ögon:
59 ögon exkluderades: inget visusvärde vid baseline

Baseline data

Baseline characteristic	Both groups	Pre-pandemic	Pandemic	p
No. of eyes, n (%)	2915 (100)	1597 (55)	1318 (45)	
Gender, n (% of patients)				
Female	1708 (63)	910 (61)	798 (65)	0.0673
Mean age (SD)	78.4 (7.9)	78.6 (8)	78.2 (7.8)	0.1195
Missing	1 (0)	1 (0)	0 (0)	
Mean ETDRS letters (SD)	62.0 (14.2)	62.5 (13.7)	61.4 (14.8)	0.0778
Symptom duration, n (% of eyes)				
0 - <2 months	1610 (55)	845 (53)	765 (58)	0.0056
2 - <4 months	587 (20)	343 (21)	244 (19)	0.0513
4 – 6 months	307 (11)	171 (11)	136 (10)	0.7620
>6 months	411 (14)	238 (15)	173 (13)	0.1814
Membrane type, n (% of eyes)				
Type 1	876 (30)	439 (27)	437 (33)	0.0003
Type 2	462 (16)	277 (17)	185 (14)	0.0275
Type 3	298 (10)	160 (10)	138 (10)	0.5793
PCV	101 (3)	63 (4)	38 (3)	0.1541
Undetermined	1036 (36)	593 (37)	443 (34)	0.1057
Missing	142 (5)	65 (4)	77 (6)	
Initial drug, n (% of eyes)				
Aflibercept	2557 (88)	1428 (89)	1129 (86)	0.0022
Ranibizumab	82 (3)	43 (3)	39 (3)	0.7359
Bevacizumab	276 (9)	126 (8)	150 (11)	0.0015
Initial treatment regimen, n (% of eyes)				
T&E	2269 (78)	1274 (80)	995 (75)	0.0053
PRN	365 (13)	179 (11)	186 (14)	0.0177
Fixed	61 (2)	37 (2)	24 (2)	0.4353
Other	72 (2)	29 (2)	43 (3)	
Missing	148 (5)	78 (5)	70 (5)	

ETDRS, Early Treatment Diabetic Retinopathy Study; PCV, polypoidal choroidal vasculopathy; T&E, Treat & Extend; PRN, Pro Re Nata

Diagnos – Metoder



Type of diagnostic imaging at baseline (excluding missing values), n (% of eyes)	Both groups	Pre-pandemic	Pandemic	p
OCT	528 (18.1)	206 (12.9)	322 (24.4)	<0.0001
OCT + FA + ICG	63 (2.2)	41 (2.6)	22 (1.7)	<0.0001
OCT + OCT-A	874 (30)	172 (10.8)	702 (53.3)	<0.0001
OCT + OCT-A + FA + ICG	129 (4.4)	52 (3.3)	77 (5.8)	0.0089
FA	5 (0.2)	4 (0.3)	1 (0.1)	0.0296
Missing value	1214 (41.6)	1091 (68.3)	123 (9.3)	

OCT, optical coherence tomography; OCT-A, optical coherence tomography angiography; FA, fluorescein angiography; ICG, indocyanine green

Resultat – Visusändring 1 år



Ingen statistiskt signifikant skillnad

Resultat – Visus & Injektioner



1-year follow-up	Pre-pandemic	Pandemic	p
Visual acuity available No. of eyes, n (%)	921 (58)	575 (44)	<0.0001
Mean change ETDRS Letters (SD)	2.6 (13.6)	3.8 (16.3)	0.1734
Mean VA examinations per patient n (SD)	4.2 (1.5)	3.5 (1.6)	<0.0001
Mean no. of injections	7.4 (2.2)	7.5 (2.3)	0.0063

Resultat – Kliniska besök



1-year follow-up	Pre-pandemic	Pandemic	p
Mean visits n (%)	12 783	10 585	
With VA testing	6 661 (52.1)	4 661 (44)	<0.0001
With injection	11 779 (92.1)	9 958 (94.1)	<0.0001
Only injection	6 103 (47.7)	5 898 (55.7)	<0.0001
Mean duration Baseline to first injection Days (SD)	4.1 (18.5)	5.2 (23.2)	<0.0001
Mean delayed visits n (% of eyes)	5 056 (45.2)	3 301 (35.6)	<0.0001
Mean length of delay Days (SD)	13.8 (22.6)	13.8 (25.8)	0.0643

Resultat – Behandlings regim

1-year follow-up	Pre-pandemic	Pandemic	p
Change of regimen from baseline No. of eyes, n (%)	570 (36)	255 (19)	<0.0001
T&E to other regimen	319 (25)	70 (7)	<0.0001
T&E to PRN	214 (67)	44 (63)	0.4891
PRN to other regimen	130 (73)	80 (43)	<0.0001
PRN to T&E	116 (89)	70 (88)	0.8237

Kan vi vara nöjda?

Symptomduration “0- <2 månader” – För långt intervall? Ändring på gång!

Baseline characteristic	Both groups	par		
Symptom duration, n (% of eyes)				
0 - <2 months	1610 (55)	845 (53)	765 (58)	0.0056
2 - <4 months	587 (20)	343 (21)	244 (19)	0.0513
4 – 6 months	307 (11)	171 (11)	136 (10)	0.7620
>6 months	411 (14)	238 (15)	173 (13)	0.1814

1-year follow-up	Pre-pandemic	Pandemic	p
Visual acuity available No. of eyes, n (%)	921 (58)	575 (44)	<0.0001

Kanske fler eller mer regelbundna visusprövningar?

Grattis



Bevarade visusvinster

Prioriterade injektionsbesök
& färre försenade besök



Ökning av icke-invasiv diagnostik